Skip to main content

Advertisement

SpringerLink
Log in

Inflammatory Breast Cancer: Is There a Role for Deescalation of Surgery?

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Inflammatory breast cancer (IBC) is a rare and aggressive presentation of breast cancer, characterized by higher propensity for locoregional recurrence and distant metastasis compared with non-IBC. Because of extensive parenchymal and overlying dermal lymphatic involvement by carcinoma, IBC is unresectable at diagnosis. Trimodality therapy (neoadjuvant chemotherapy followed by modified radical mastectomy and adjuvant comprehensive chest wall and regional nodal radiotherapy) has been a well-accepted treatment algorithm for IBC. Over the last few decades, several innovations in systemic therapy have resulted in rising rates of pathologic complete response (pCR) in both the affected breast and the axilla. The latter may present an opportunity for deescalation of lymph node surgery in patients with IBC, as those with an axillary pCR may be able to avoid an axillary dissection. To this end, feasibility data are necessary to address this question. There are very limited data on the safety of breast conservation of IBC; therefore, mastectomy remains the standard of care for this disease. There are also no data addressing the safety of immediate reconstruction in patients with IBC. Considering that some degree of deliberate skin-sparing to facilitate immediate breast reconstruction would be expected, given the extensive skin involvement by disease at diagnosis, the safest oncologic strategy to breast reconstruction in IBC would be the delayed approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Walker WM. The management of inflammatory carcinoma of the breast. J Natl Med Assoc. 1971;63(5):330–1.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Lee BJ, Tannenbaum NE. Inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1924;39:580–95.

    Google Scholar 

  3. Rea D, Francis A, Hanby AM, et al. Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. Br J Cancer. 2015;112(9):1613–5. https://doi.org/10.1038/bjc.2015.115.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. White RE, Warren LE, Bellon JR, et al. Abstract P6–14-08: Risk factors for developing inflammatory breast cancer: unique trends among a single patient population. Cancer Res. 2015;75(9_suppl):P6-14–08.

    Article  Google Scholar 

  5. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A pathologic definition. Cancer. 1974;33(4):1045–7. https://doi.org/10.1002/1097-0142(197404)33:4%3c1045::aid-cncr2820330422%3e3.0.co;2-m.

    Article  CAS  PubMed  Google Scholar 

  6. Wang CC. Management of inflammatory carcinoma of the breast. Int J Radiat Oncol Biol Phys. 1978;4(7–8):709–10. https://doi.org/10.1016/0360-3016(78)90200-6.

    Article  CAS  PubMed  Google Scholar 

  7. Buzdar AU, Montague ED, Barker JL, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of breast with combined modality approach—an update. Cancer. 1981;47(11):2537–42. https://doi.org/10.1002/1097-0142(19810601)47:11%3c2537::aid-cncr2820471102%3e3.0.co;2-x.

    Article  CAS  PubMed  Google Scholar 

  8. Fields JN, Kuske RR, Perez CA, Fineberg BB, Bartlett N. Prognostic factors in inflammatory breast cancer. Univariate and multivariate analysis Cancer. 1989;63(6):1225–32. https://doi.org/10.1002/1097-0142(19890315)63:6%3c1225::aid-cncr2820630632%3e3.0.co;2-5.

    Article  CAS  PubMed  Google Scholar 

  9. Fleming RY, Asmar L, Buzdar AU, et al. Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma. Ann Surg Oncol. 1997;4(6):452–61. https://doi.org/10.1007/BF02303668.

    Article  CAS  PubMed  Google Scholar 

  10. Liao Z, Strom EA, Buzdar AU, et al. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence. Int J Radiat Oncol Biol Phys. 2000;47(5):1191–200. https://doi.org/10.1016/s0360-3016(00)00561-7.

    Article  CAS  PubMed  Google Scholar 

  11. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(2):474–84. https://doi.org/10.1016/j.ijrobp.2008.01.039.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Rueth NM, Lin HY, Bedrosian I, et al. Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. J Clin Oncol. 2014;32(19):2018–24. https://doi.org/10.1200/JCO.2014.55.1978.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–6. https://doi.org/10.1200/JCO.2011.40.8369.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–56. https://doi.org/10.1245/s10434-015-4921-5.

    Article  PubMed  Google Scholar 

  15. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804. https://doi.org/10.1200/JCO.2011.38.8595.

    Article  Google Scholar 

  16. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342–54. https://doi.org/10.1016/j.ejca.2012.05.023.

    Article  CAS  PubMed  Google Scholar 

  17. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. https://doi.org/10.1056/NEJMoa1910549.

    Article  CAS  PubMed  Google Scholar 

  18. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106(5):1000–6. https://doi.org/10.1002/cncr.21726.

    Article  PubMed  Google Scholar 

  19. Nakhlis F, Regan MM, Warren LE, et al. The Impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer. Ann Surg Oncol. 2017;24(9):2563–9. https://doi.org/10.1245/s10434-017-5903-6.

    Article  PubMed  Google Scholar 

  20. Postlewait LM, Teshome M, DeSnyder SM, et al. Factors associated with pathological node negativity in inflammatory breast cancer: are there patients who may be candidates for a de-escalation of axillary surgery? Ann Surg Oncol. 2020;27(12):4603–12. https://doi.org/10.1245/s10434-020-08891-y.

    Article  PubMed  Google Scholar 

  21. van Uden DJP, van Maaren MC, Bult P, et al. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer. Breast Cancer Res Treat. 2019;176(1):217–26. https://doi.org/10.1007/s10549-019-05219-7.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033–41. https://doi.org/10.1002/bjs.11469.

    Article  CAS  PubMed  Google Scholar 

  23. Fayanju OM, Ren Y, Greenup RA, et al. Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. Breast Cancer Res Treat. 2020;180(1):207–17. https://doi.org/10.1007/s10549-020-05529-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hieken TJ, Murphy BL, Boughey JC, Degnim AC, Glazebrook KN, Hoskin TL. Influence of biologic subtype of inflammatory breast cancer on response to neoadjuvant therapy and cancer outcomes. Clin Breast Cancer. 2018;18(4):e501–6. https://doi.org/10.1016/j.clbc.2017.10.003.

    Article  PubMed  Google Scholar 

  25. Liu J, Chen K, Jiang W, et al. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. J Cancer Res Clin Oncol. 2017;143(1):161–8. https://doi.org/10.1007/s00432-016-2281-6.

    Article  CAS  PubMed  Google Scholar 

  26. Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–64. https://doi.org/10.1200/JCO.2014.55.7827.

    Article  PubMed  Google Scholar 

  27. Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–61. https://doi.org/10.1001/jama.2013.278932.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18. https://doi.org/10.1016/S1470-2045(13)70166-9.

    Article  PubMed  Google Scholar 

  29. Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: a national cancer database analysis. Ann Surg Oncol. 2019;26(11):3517–25. https://doi.org/10.1245/s10434-019-07583-6.

    Article  PubMed  Google Scholar 

  30. Hidar S, Bibi M, Gharbi O, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer. Int J Surg. 2009;7(3):272–5. https://doi.org/10.1016/j.ijsu.2009.04.012.

    Article  PubMed  Google Scholar 

  31. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol. 2002;9(3):235–42. https://doi.org/10.1007/BF02573060.

    Article  PubMed  Google Scholar 

  32. DeSnyder SM, Mittendorf EA, Le-Petross C, et al. Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer. Clin Breast Cancer. 2018;18(1):e73–7. https://doi.org/10.1016/j.clbc.2017.06.014.

    Article  PubMed  Google Scholar 

  33. Andreis D, Bonardi S, Allevi G, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. Breast. 2016;29:55–61. https://doi.org/10.1016/j.breast.2016.07.003.

    Article  CAS  PubMed  Google Scholar 

  34. Clinicaltrials.gov. Safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-exposure prophylaxis in hiv-uninfected cisgender men and transgender women who have sex with men. https://clinicaltrials.gov/ct2/show/NCT02720094. Accessed 4 May 2022.

  35. Brzezinska M, Williams LJ, Thomas J, Michael Dixon J. Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery. Breast Cancer Res Treat. 2016;160(3):387–91. https://doi.org/10.1007/s10549-016-4017-3.

    Article  CAS  PubMed  Google Scholar 

  36. Muzaffar M, Johnson HM, Vohra NA, Liles D, Wong JH. The impact of locoregional therapy in nonmetastatic inflammatory breast cancer: a population-based study. Int J Breast Cancer. 2018;2018:6438635. https://doi.org/10.1155/2018/6438635.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Evans GR, Schusterman MA, Kroll SS, et al. Reconstruction and the radiated breast: is there a role for implants? Plast Reconstr Surg. 1995;96(5):1111–5 (discussion, 1116–8).

    Article  CAS  Google Scholar 

  38. Rubino C, Figus A, Lorettu L, Sechi G. Post-mastectomy reconstruction: a comparative analysis on psychosocial and psychopathological outcomes. J Plast Reconstr Aesthet Surg. 2007;60(5):509–18. https://doi.org/10.1016/j.bjps.2006.06.013.

    Article  PubMed  Google Scholar 

  39. Baumann DP, Crosby MA, Selber JC, et al. Optimal timing of delayed free lower abdominal flap breast reconstruction after postmastectomy radiation therapy. Plast Reconstr Surg. 2011;127(3):1100–6. https://doi.org/10.1097/PRS.0b013e3182043652.

    Article  CAS  PubMed  Google Scholar 

  40. Chin PL, Andersen JS, Somlo G, Chu DZ, Schwarz RE, Ellenhorn JD. Esthetic reconstruction after mastectomy for inflammatory breast cancer: Is it worthwhile? J Am Coll Surg. 2000;190(3):304–9.

    Article  CAS  Google Scholar 

  41. Chang EI, Chang EI, Ito R, et al. Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. Plast Reconstr Surg. 2015;135(2):262e-e269. https://doi.org/10.1097/PRS.0000000000000900.

    Article  CAS  PubMed  Google Scholar 

  42. Nakhlis F, Regan MM, Chun YS, et al. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute’s Inflammatory Breast Cancer Program experience. Breast J. 2020;26(3):384–90. https://doi.org/10.1111/tbj.13509.

    Article  PubMed  Google Scholar 

  43. Hoffman DI, Santos PMG, Goldbach M, et al. Immediate breast reconstruction for inflammatory breast cancer: trends in use and clinical outcomes 2004–2016. Ann Surg Oncol. 2021;28(13):8789–801. https://doi.org/10.1245/s10434-021-10404-4.

    Article  PubMed  Google Scholar 

  44. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2022. 2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 4 May 2022.

Download references

Funding

None.

Author information

Authors and Affiliations

  1. Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, MA, USA

    Faina Nakhlis MD

  2. Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA

    Faina Nakhlis MD

  3. Harvard Medical School, Boston, MA, USA

    Faina Nakhlis MD

Authors
  1. Faina Nakhlis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Faina Nakhlis MD.

Ethics declarations

Disclosures

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakhlis, F. Inflammatory Breast Cancer: Is There a Role for Deescalation of Surgery?. Ann Surg Oncol 29, 6106–6113 (2022). https://doi.org/10.1245/s10434-022-12138-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12138-3

Search

Navigation